Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: the upside, a game of cues

January 3, 2018 7:18am

Be very careful of the pump and/or dump agendas by the 12^th of January

With JPMorgan next week after three (3) sessions this week and four (4) days next week

As I had stated, “While volume was all over the map, luckily to the upside; we are still playing chutes and ladders - the exciting game of ups and downs!”

Two (2) words – patience and discipline in stepping into the New Year as to momentum!

Pre-open indications: 4 SELLs and 1 BUY

Higher open expected

Dow futures are UP +16% (+40 points) and NASDAQ futures are UP +0.20% (+13 points)

U.S. stock index futures pointed to a higher open on Wednesday, as investors turned their attention away from geopolitical tensions and toward upcoming economic news and data.

European markets were higher, as retail stocks led the gains on a day when investors reacted to the release of sweeping reforms for the continent's financial sector.

Asian stocks closed with moderate gains, tracking sizable increases seen on Wall Street overnight as the dollar traded near three-month lows.

Issues that will affect the trading day: all eyes are on the Federal Open Market Committee (FOMC) minutes. The document, due out at 2 p.m. ET, will contain the minutes of the U.S. central bank's most recent meeting.

Data docket: Mortgage applications are set to be released at 7 a.m. ET, followed by the manufacturing ISM report on business and construction spending, both due out at 10 a.m. ET.

Issues on the political front: Geopolitics will also continue to put global markets on edge during today's session. On Tuesday, President Donald Trump tweeted that that his "nuclear button" was "much bigger and more powerful" than the one controlled by North Korea's leader Kim Jong-un.

Henry’omics:

From Tuesday night’s closing bell post, “a serious and positive upswing in a new month, year and day with many in lust for the upside, but love lasts longer than a session. What worked today, didn’t work last year … as the downtrodden and oversold raised their heads above the dust.”

I also stated, “While volume was all over the map, luckily to the upside …we playing chutes and ladders - the exciting game of ups and downs?”

I’d wait to have five (5) full days of trading under my belt before I consider being – TOO long!

Two words – patience and discipline in stepping into the New Year as to trading or investing!

When the headwind appears from somewhere, expect it to dissipate of blow itself out!

The cell therapy sector’s record over 5 sessions (of 40 covered companies): The RegMed and cell therapy sector closed POSITIVE on Tuesday, a New Year holiday on Monday, NEGATIVE on Thursday and POSITIVE last Wednesday:

· Tuesday closed POSITIVE with 7 decliners, 31 advancers and 2 flats;

· Monday was NEW Year’s day;

· Friday closed NEGATIVE with 25 decliners, 14 advancers and 1 flat;

· Thursday closed NEGATIVE with 20 decliners, 15 advancers and 5 flats;

· Last Wednesday closed POSITIVE with 17 decliners, 20 advancers and 3 flats;

Today’s indications:

The iShares Nasdaq Biotechnology (IBB) is indicating a NEGATIVE -0.04% in Wednesday’s pre-market;
The SPDR S&P Biotech ETF (XBI) is indicating NOT in Wednesday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Wednesday’s pre-open;
The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.0.01% in Wednesday’s pre-open

Companies in my headlights:

Biostage (BSTGD) post a 1-for-20 reverse closed up +$0.33 or 38.38% to $1.22. What are day traders betting on? There are no scientists, only a CEO, CFO and 2 accountants left in a building they have paid rent on. Won’t it be interesting on the announced and soon to be conference call as the CEO explains, doesn’t and obfuscates the facts of the past year and its effect upon the previous and disenfranchised shareholders. Also it meets my 15% threshold, don’t blink an eye – SELL;

Cellectis SA (CLLS) closed up +$0.94 or +3.22% to $30.09. Last time, I saw $35.01 was on 10/31/16However, the aftermarket indication is a negative -$2.94 or -9.77% - SELL;

Intrexon (XON) closed up +$1.95 or +16.93% to $13.47 with 3.847 M shares traded <3 month average = 1.421 M shares>. Overbought, also my 15% threshold was met. The last I saw 12/1’s pricing was $13.55 which also dropped to $13.42 on 12/4 and was $12.94 on 12/5. The aftermarket indication is a negative -$0.02 or -0.15% – SELL;

Neuralstem (CUR) closed up +$0.31 or +18.02% to $2.03 with 438.1 K shares traded <3 month average = 1.52 M shares>. When was the last time, you saw $2.03, 12/19, 12/15 as compared to 12/1’s $1.17. Oversold and another exceeding my 15% threshold. The aftermarket indication is a negative -$0.03 or -1.48% - SELL;

Sangamo Therapeutics (SGMO) closed up +$1.15 or 7.01% to $17.55. The pre-market indication is a positive +$0.60 or +3.39% after news of the company's $12 million collaboration with Pfizer Inc. on a gene therapy for two neurodegenerative disorders, amyotrophic lateral sclerosis and frontotemporal lobar degeneration. SGMO which will be responsible for development will also be eligible for up to $150 million in milestone payments, plus royalties on net sales. Pfizer (PFE) will handle and pay for further development and commercialization for the program and any resulting products; company shares rose 0.2% in premarket trade. Mutations in a certain gene, C9ORF72, are linked to both ALS and FTLD, resulting in motor neuron deterioration for ALS patients and frontal and temporal lobe neuron deterioration for FTLD patients. Neither disorder currently has a cure. The collaboration will use SGMO's zinc finger protein technology, which engineers zinc finger proteins to recognize specific DNA sequences, in the hope of developing a one-time treatment that would "down-regulate expression of the mutant form of the gene." – BUY;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.